Interview with Igor Kouznetsov, General Director, Euroservice
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
Address: 141400, Moscow region, Khimki2-d, Rabochaya str., bld. 1,Russia
Tel: +7 (495) 925-30-74
History of the Center began in 1990 and is associated with the name of its founder – Alexander Vasilievich Ivaschenko – a Scientific Advisor, a Doctor of Chemistry, a Professor, an Honored Innovator of the RSFSR, a Laureate of State prize of the USSR and Award of Council of Ministers of the USSR.
Alexander Vasilievich established the first organization of the Center – a scientific and consulting enterprise named “Contact-Service”. Within frames of this company we started works in the field of complex ordered organic synthesis for such scientific catalogue companies as Aldrich, Fluka, Acros, Merck etc. Since 1995 chemical laboratories of “Contact-Service” were among first who started absorbtion of methods for parallel and combinatorial synthesis of the libraries of organic compounds for a high-throughput screening on up-to-date biotargets with the aim to determinate theirs biological activity. Starting from this moment swift development of international cooperation with the leading biotechnological and pharmaceutical companies of Europe, America and Japan had been launched.
Rapid development of a high-throughput screening as an industrial technology for searching of new drug candidates turned these technologies into industrial standard for major world pharmaceutical companies. This event enabled to conduct dozens of thousands biological tests on substances per day. This in turn demanded millions of new substances for examinations. In this period of time Alexander Vasilievich invited to work as main partners his son, Andrei Ivaschenko, and a friend of him, Nikolai Savchuk, – both has implemented international projects in the field of informational systems before. Since 1998 main conceptions of scientific and investing development had been worked out, future managing company of Center of High Technologies “ChemRar” and its “anchor” R&D organization – Chemical Diversity Research Institute Ltd. (CDRI Ltd.)-was created.
Starting from 2001 self-unique technologies and developments emerged. They were highly valued by international scientific community. Taking into consideration success of long-term cooperation, partners of “CDRI” Ltd. were proposing to find investors for establishing a research center within the territory of the RF, which would be working in the field of pre-clinic development of medical drugs. To execute this project in 2003-2004 we purchased a laboratory building which was in emergency state and was located at the site of a former national enterprise – the Research Institute of Radio and Professional Equipment in Khimki city, Moscow region – and managed to repair it within one year. As a result an advanced business-incubator of high-tech innovative companies was founded – Center of High Technologies “ChemRar”.
In 2005 on the basis of CHT “ChemRar” we established “RMPC CITOLEX” Ltd. which is working out, organizing and introducing into production the combinatorial medical drug called “SPASCARD” for self- and mutual assistance during heart attack.
Since 2007 CHT “ChemRar” in liaison with the Federal Science and Innovation Agency (ROSNAUKA) started a joint financing on a parity basis of a three-year project for development series of high efficient clinical candidates for treatment of infectious diseases. The project was set up on the basis of the Yaroslavl State Pedagogic University and called “Intellectual Dialog” Ltd.
With the object of spreading a complex of services and products for pre-clinical development of innovative medical drugs proposed by CHT “ChemRar” to its partners, in 2008 we created “Drug Technology” Ltd. on the basis of the Center and organized producing of a full cycle of import substitutive synthetic generics. In 2009 “Prudentas” Ltd. entered into the Group of companies. “Prudentas” Ltd. presents one of the leading Russian contract organization conducting early stages of clinical researches in the territory of Russia.
ChemRar is Russia’s premier biopharmaceutical development incubator.
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here